부산대학교 도서관

Bercu, Joel P.; Ponting, David J.; Ripp, Sharon L.; Dobo, Krista L.; Totah, Rheem A.; Bolleddula, Jayaprakasam

Clinical Pharmacology & Therapeutics; Jul2024, Vol. 116 Issue 1, p34-37, 4p

Burris HA; Sarah Cannon Research Institute, Nashville, TN, USA. howard.burris@scri.com.; Berlin J; Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.; Arkenau T; Drug Development, Ellipses Pharma, London, UK.; Cote GM; Division of Hematology and Oncology, Mass General Cancer Center, Boston, MA, USA.; Lolkema MP; Department of Medical Oncology, Erasmus MC Cancer Institute, Utrecht, Netherlands.; Amgen Inc., Thousand Oaks, CA, USA.; Ferrer-Playan J; Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Eysins, Switzerland.; Kalapur A; Global Patient Safety Oncology, Merck Healthcare KGaA, Darmstadt, Germany.; Bolleddula J; Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, USA.; Locatelli G; Clinical Biomarkers, Merck Healthcare KGaA, Darmstadt, Germany.; Goddemeier T; Biostatistics, Merck Healthcare KGaA, Darmstadt, Germany.; Gounaris I; Global Clinical Development, Merck Serono Ltd., an affiliate of Merck KGaA, Feltham, UK.; de Bono J; Division of Clinical Studies, Institute of Cancer Research, London, UK.; Royal Marsden, Hospital, London, UK.

Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

Bolleddula, D. A.; Dillon, H. E.; Alliseda, A.; Bhosale, P.; Berg, J. C.

Wang D; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA USA.; Bolleddula J; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA USA.; Coenen-Stass A; Merck Healthcare KGaA, Darmstadt, Germany.; Grombacher T; Merck Healthcare KGaA, Darmstadt, Germany.; Dong JQ; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA USA.; Scheuenpflug J; Merck Healthcare KGaA, Darmstadt, Germany.; Locatelli G; Merck Healthcare KGaA, Darmstadt, Germany.; Feng Z; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA USA.

Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 100897350 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8042 (Electronic) Linking ISSN: 14622416 NLM ISO Abbreviation: Pharmacogenomics Subsets: MEDLINE

Scheible H; NCE DMPK Merck Healthcare KGaA, Darmstadt, Germany.; Schieferstein H; NCE DMPK Merck Healthcare KGaA, Darmstadt, Germany.; Schmidt R; EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany.; Pusecker K; NCE DMPK Merck Healthcare KGaA, Darmstadt, Germany.; Gradhand U; NCE DMPK Merck Healthcare KGaA, Darmstadt, Germany.; Gopalakrishnan S; Quantitative Pharmacology Merck Healthcare KGaA, Darmstadt, Germany.; Iqbal K; Quantitative Pharmacology Merck Healthcare KGaA, Darmstadt, Germany.; Dong J; EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany.; Jones R; EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany.; Meli C; Merck Ltd, Piedmont, Italy, an affiliate of Merck KGaA, Darmstadt, Germany.; Bolleddula J; EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany.; Dyroff M; EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany.; Georgi K; NCE DMPK Merck Healthcare KGaA, Darmstadt, Germany.

Publisher: Informa Healthcare Country of Publication: England NLM ID: 1306665 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1366-5928 (Electronic) Linking ISSN: 00498254 NLM ISO Abbreviation: Xenobiotica Subsets: MEDLINE

Izat N; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Bolleddula J; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Abbasi A; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Cheruzel L; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Jones RS; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Moss D; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Ortega-Muro F; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Parmentier Y; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Peterkin VC; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Tian DD; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Venkatakrishnan K; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Zientek MA; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Barber J; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Houston JB; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Galetin A; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.).; Scotcher D; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.) daniel.scotcher@manchester.ac.uk.

Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

Hariparsad N; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts, USA.; Ramsden D; Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.; Taskar K; Drug Metabolism and Pharmacokinetics, IVIVT, GlaxoSmithKline, Stevenage, UK.; Badée J; PK Sciences, Novartis Institutes for Biomedical Research, Basel, Switzerland.; Venkatakrishnan K; EMD Serono Research & Development Institute, Inc, Billerica, Massachusetts, USA.; Merck KGaA, Darmstadt, Germany.; Reddy MB; Department of Clinical Pharmacology, Oncology, Pfizer, Boulder, Colorado, USA.; Cabalu T; Merck & Co., Inc., Kenilworth, New Jersey, USA.; Mukherjee D; Clinical Pharmacology & Pharmacometrics, AbbVie, Inc., North Chicago, Illinois, USA.; Rehmel J; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.; Bolleddula J; EMD Serono Research & Development Institute, Inc, Billerica, Massachusetts, USA.; Merck KGaA, Darmstadt, Germany.; Emami Riedmaier A; Bristol Meyers Squibb, Princeton, New Jersey, USA.; Prakash C; Agios Pharmaceuticals, Cambridge, Massachusetts, USA.; Chanteux H; UCB Biopharma, QP-DMPK, Brussels, Belgium.; Mao J; Department of Drug Metabolism and Pharmacokinetics, Genentech, A Member of the Roche Group, South San Francisco, California, USA.; Umehara K; Pharmaceutical Sciences, Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Shah K; Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.; De Zwart L; DMPK, Janssen Research and Development, Beerse, Belgium.; Dowty M; Department of Pharmacokinetics, Dynamic, and Metabolism, Pfizer, Cambridge, Massachusetts, USA.; Kotsuma M; Quantitative Clinical Pharmacology, Daiichi-Sankyo, Inc., New Jersey, USA.; Li M; Pharmacokinetics, Dynamics and Metabolism, Sanofi, Bridgewater, New Jersey, USA.; Pilla Reddy V; Clinical Pharmacology and Pharmacometrics, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.; McGinnity DF; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Parrott N; Pharmaceutical Sciences, Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.

Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE

Bolleddula J; Cornell University, Ithaca, NY, USA.; Simeon D; The University of the West Indies, St Augustine, Trinidad and Tobago.; Anderson SG; Glasgow Caribbean Centre for Development Research, The University of the West Indies, Cave Hill, Barbados.; Shields L; The University of the West Indies, Mona, Jamaica.; Mullings J; The University of the West Indies, Mona, Jamaica.; Ossorio P; University of Wisconsin, Madison, WI, USA.; Bethelmey A; The University of the West Indies, St Augustine, Trinidad and Tobago.; Perkins AK; The University of the West Indies, Regional Headquarters, Jamaica.

Publisher: Elsevier Ltd Country of Publication: England NLM ID: 9918232503006676 Publication Model: eCollection Cited Medium: Internet ISSN: 2667-193X (Electronic) Linking ISSN: 2667193X NLM ISO Abbreviation: Lancet Reg Health Am Subsets: PubMed not MEDLINE

Bolleddula J; Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.; Gopalakrishnan S; Merck KGaA, Darmstadt, Germany.; Hu P; Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.; Dong J; Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.; Venkatakrishnan K; Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.

Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE

Bolleddula J; Takeda Development Center Americas, Inc., Lexington, Massachusetts swapan@bostonpharmaceuticals.com bolleddulajp@yahoo.com.; Chen H; Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Cohen L; Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Zhou X; Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Pusalkar S; Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Berger A; Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Sedarati F; Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Venkatakrishnan K; Takeda Development Center Americas, Inc., Lexington, Massachusetts.; Chowdhury SK; Takeda Development Center Americas, Inc., Lexington, Massachusetts swapan@bostonpharmaceuticals.com bolleddulajp@yahoo.com.

Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE